The tumor microenvironment alters the immune response by modulating the splicing of interferon regulatory factor 1 (IRF1), a key transcription factor in Th1 cells, resulting in the production of different IRF1 protein isoforms with altered activity [166]. This evidence concerns the gene IRF1 and neoplasm.